Clinical trials: Microangiopathy, active
aHUS - Atypical Hemolytic Uremic Syndrome
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.
- Trial name
- NCT05684159
- Testing
- NM8074
- Volunteers
- 12 people
- Sponsor
- NovelMed Therapeutics
Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
Safety and Efficacy of Eculizumab in High-risk TA-TMA
High-risk, complement-mediated, untreated transplant-associated thrombotic microangiopathy (hrTA-TMA) carries a very poor prognosis due to multiple organ dysfunction syndrome (MODS).
- Trial name
- NCT07707687
- Testing
- Eculizumab
- Where
- 8 sites in China
- Volunteers
- 24 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Microangiopathy, Kidney Transplant
Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant Centre
It is a retrospective-prospective, single-centre, non-pharmacological, retrospective tissue study carried out for scientific and health protection purposes.
- Trial name
- PT-TMA2022 (NCT06759961)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Microangiopathy, Microvascular Complications
Microangiopathy in Diabetes
This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with…
- Trial name
- MIND (NCT07145567)
- Where
- Sweden
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Cerebral Cavernous Malformation, Cavernous Angioma
Biomarkers of CASH
The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans.
- Conditions
- Cerebral Cavernous Malformation, Cavernous Angioma, Hemorrhagic Microangiopathy
- Trial name
- NCT04467489
- Testing
- observational
- Where
- 4 sites in United States
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
The goal of this clinical trial is to evaluate the efficacy and safety of Iptacopan as a second-line treatment for high-risk hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA).
- Trial name
- NCT07347990
- Testing
- iptacopan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical
Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions.
- Conditions
- Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical, Hemolytic-Uremic Syndrome
- Trial name
- COMPETE (NCT04745195)
- Where
- Netherlands
- Volunteers
- 42 people
- Sponsor
- Maastricht University Medical Center
Atypical Hemolytic Uremic Syndrome
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study participants with aHUS.
- Trial name
- NCT05935215
- Testing
- Iptacopan
- Where
- 31 sites in China, France and 6 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.
- Trial name
- NCT05795140
- Testing
- Iptcaopan 200 mg
- Where
- 9 sites in Brazil, China and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
TTP - Thrombotic Thrombocytopenic Purpura
Italian iTTP Registry
ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients…
- Trial name
- NCT06376786
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Fondazione Luigi Villa
Thrombotic Microangiopathies
The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy
Study rationale: Viral infections, such as CMV, are a risk factor for TA-TMA (transplantation-associated TMA). Viral infections increase interferon (IFN) levels and high IFN levels are associated with thrombotic microangiopathy…
- Trial name
- ROSARIO (NCT07705789)
- Testing
- blood draw, urine collection
- Where
- 3 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Sofie Dhaese
Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy
A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy
This study aims to explore the preliminary clinical efficacy and safety of NPDR-01 eye drops in patients with non-proliferative diabetic retinopathy (NPDR).
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy, Retinal Microaneurysms, Diabetic Retinopathy
- Trial name
- NCT07198815
- Testing
- Investigational Eye Drops (NPDR-01)
- Volunteers
- 10 people
- Sponsor
- Sichuan Academy of Medical Sciences
Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
TGD001 Treatment in Thrombotic Microangiopathies
This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or…
- Trial name
- NCT07459114
- Testing
- TGD001
- Volunteers
- 70 people
- Sponsor
- TargED Biopharmaceuticals B.V.
Thrombotic Microangiopathies
Construction of a Database for TMA
Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software.
- Trial name
- NCT05634928
- Testing
- collection data
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Microangiopathy, Macroangiopathy
Poznan Prospective Study of Type 1 Diabetic Patients
The purpose of this study is to evaluate the development and progression of chronic complications (retinopathy, neuropathy, diabetic chronic renal disease, cardiovascular events) in patients with type 1 diabetes treated from the…
- Conditions
- Microangiopathy, Macroangiopathy, Insulin Treatment Overcorrection, Insulin Resistance
- Trial name
- PoProStu (NCT01411033)
- Volunteers
- 100 people
- Sponsor
- Poznan University of Medical Sciences
GVHD - Graft-Versus-Host Disease, Infections After HSCT
Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for people with severe blood-related diseases.
- Conditions
- GVHD - Graft-Versus-Host Disease, Infections After HSCT, Transplant Associated Microangiopathy TAM, Sinusoidal Obstruction Syndrome (SOS)
- Trial name
- NCT06715046
- Testing
- Sample collation for cfDNA methylation analysis, Sample collection for EV phenotype analysis
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT05855083
- Testing
- Biological: narsoplimab
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Thrombotic Microangiopathy
Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients
Thrombotic Microangiopathy (TMA) Associated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a serious complication that is associated with increased morbidity, related to multiple organ failure, with increased…
- Trial name
- NCT07059026
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- ITAC (Instituto de Trasplantes y Alta Complejidad)
Transsexualism, Transgenderism
Effects of Cross-sex Hormone Therapy on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System
Current study aims to characterize five highly interconnected physiological systems in patients undergoing cross-sex hormone therapy - namely glucose and lipid metabolism, energy balance, eating behavior, functional brain…
- Conditions
- Transsexualism, Transgenderism, Adiposity, Eating Behavior
- Trial name
- HHS (NCT04838249)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Leipzig